Shares of BELLUS Health Inc. (TSE:BLU – Get Free Report) were down 0.1% on Monday . The stock traded as low as C$19.24 and last traded at C$19.48. Approximately 28,666 shares traded hands during trading, a decline of 52% from the average daily volume of 59,471 shares. The stock had previously closed at C$19.50.
BELLUS Health Stock Down 0.1 %
The stock’s 50-day moving average is C$19.48. The company has a quick ratio of 16.40, a current ratio of 33.42 and a debt-to-equity ratio of 0.32. The company has a market cap of C$2.47 billion, a P/E ratio of -20.29 and a beta of -0.28.
BELLUS Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Further Reading
- Five stocks we like better than BELLUS Health
- Consumer Staples Stocks, Explained
- Real Estate Stock Signals a Boom in Manufacturing Activity
- What is the Shanghai Stock Exchange Composite Index?
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- 3 Warren Buffett Stocks to Buy Now
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
